Reaction Details |
| Report a problem with these data |
Target | Dual specificity mitogen-activated protein kinase kinase 4 |
---|
Ligand | BDBM50053313 |
---|
Substrate/Competitor | Mitogen-activated protein kinase 14 |
---|
Meas. Tech. | ADP-Glo Kinase Activity Assay |
---|
IC50 | 1300±n/a nM |
---|
Citation | Scheidt, KA; Schiltz, GE; Clutter, MR; Kwong, AJ 3-arylindazoles as selective MEK4 inhibitors US Patent US11370770 Publication Date 6/28/2022 |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Dual specificity mitogen-activated protein kinase kinase 4 |
---|
Name: | Dual specificity mitogen-activated protein kinase kinase 4 |
Synonyms: | JNK-activating kinase 1 | JNKK | JNKK1 | MAP kinase kinase 4 | MAP2K4 | MEK4 | MKK4 | MP2K4_HUMAN | PRKMK4 | SAPK/ERK kinase 1 | SEK1 | SERK1 | SKK1 | c-Jun N-terminal kinase kinase 1 |
Type: | PROTEIN |
Mol. Mass.: | 44294.29 |
Organism: | Homo sapiens (Human) |
Description: | ChEMBL_1460558 |
Residue: | 399 |
Sequence: | MAAPSPSGGGGSGGGSGSGTPGPVGSPAPGHPAVSSMQGKRKALKLNFANPPFKSTARFT
LNPNPTGVQNPHIERLRTHSIESSGKLKISPEQHWDFTAEDLKDLGEIGRGAYGSVNKMV
HKPSGQIMAVKRIRSTVDEKEQKQLLMDLDVVMRSSDCPYIVQFYGALFREGDCWICMEL
MSTSFDKFYKYVYSVLDDVIPEEILGKITLATVKALNHLKENLKIIHRDIKPSNILLDRS
GNIKLCDFGISGQLVDSIAKTRDAGCRPYMAPERIDPSASRQGYDVRSDVWSLGITLYEL
ATGRFPYPKWNSVFDQLTQVVKGDPPQLSNSEEREFSPSFINFVNLCLTKDESKRPKYKE
LLKHPFILMYEERAVEVACYVCKILDQMPATPSSPMYVD
|
|
|
BDBM50053313 |
---|
Mitogen-activated protein kinase 14 |
---|
Name: | Mitogen-activated protein kinase 14 |
Synonyms: | CSAID-binding protein | CSBP | CSBP1 | CSBP2 | CSPB1 | Cytokine suppressive anti-inflammatory drug-binding protein | MAP kinase 14 | MAP kinase MXI2 | MAP kinase p38 alpha | MAPK 14 | MAPK14 | MAX-interacting protein 2 | MK14_HUMAN | MXI2 | Mitogen-activated protein kinase p38 alpha | SAPK2A | Stress-activated protein kinase 2a | p38 MAP kinase alpha/beta |
Type: | Serine/threonine-protein kinase |
Mol. Mass.: | 41286.76 |
Organism: | Homo sapiens (Human) |
Description: | Q16539 |
Residue: | 360 |
Sequence: | MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQ
SIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQ
KLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMT
GYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVG
TPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAA
QALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES
|
|
|